Progression from Chronic Atrophic Gastritis to Gastric Cancer; Tangle, Toggle, Tackle with Korea Red Ginseng by Kim, Yoon Jae et al.
195
Review J. Clin. Biochem. Nutr., 46, 195–204, May 2010
JCBN Journal of Clinical Biochemistry and Nutrition 0912-0009 1880-5086 the Society for Free Radical Research Japan Kyoto, Japan jcbn10-03 10.3164/jcbn.10-03 Review Progression from Chronic Atrophic Gastritis to Gastric Cancer; 
Tangle, Toggle, Tackle with Korea Red Ginseng
Yoon Jae Kim1, Jun Won Chung1, So Jung Lee1, Ki Seok Choi2, Ju Hyun Kim1 
and Ki Baik Hahm1,2,*
1Department of Gastroenterology Gachon Graduate School of Medicine, 
7-45 Songdo-dong, Yeonsu-gu, Incheon 406-840, Korea
2Lab of Translational Medicine Gachon University Lee Gil Ya Cancer and Diabetes Institute, 
7-45 Songdo-dong, Yeonsu-gu, Incheon 406-840, Korea
5 2010 10 4 2010 46 3 195 204 Received 4.1.2010 ; accepted 15.1.2010
*To whom correspondence should be addressed.    
Tel: +82 32 899-6055    Fax: +82 32 899-6054    
E-mail: hahmkb@gachon.ac.kr
Received 4 January, 2010; Accepted 15 January, 2010; Published online 10 April, 2010
Copyright © 2010 JCBN Summary Key molecular players that link inflammation to carcinogenesis are prostaglandins,
cytokines, nuclear factor-κB (NF-κB), chemokines, angiogenic growth factors, and free radicals,
all of which lead to increased mutations and altered functions of important enzymes and
proteins, for example, activation of oncogenic products and/or inhibition of tumor suppressor
proteins, in inflamed tissues, thus contributing to multi-stage carcinogenesis process. Inter-
preted reversely, the identification of the molecular mechanisms by which chronic inflam-
mation increases cancer risk or optimal intervention of targeted drugs or agents during the
inflammation-associated carcinogenic process could be a necessary basis for developing new
strategy of cancer prevention at many sites. In this review, we discuss the possibilities for
cancer prevention by controlling inflammation process in Helicobacter pylori ( H. pylori)-
associated inflamed stomach with Korea red ginseng. Korea red ginseng is a good example of
a natural herb that has ubiquitous properties that are conductive to stop inflammatory
carcinogenesis that is un wanted outcome of H. pylori infection, rendering rejuvenation of
chronic atrophic gastritis.
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Connection between Inflammation and Cancer
Carcinogenesis is a long and multi-step process that
includes initiation, promotion and progression as a con-
sequence of an imbalance between cell proliferation and cell
death, during which complex interplay concerning inflam-
mation between epithelial layer and mesenchymal tissues
occurred, after which more genetic and epigenetic events are
required to drive from initiated cells to malignant tumors,
each conferring one and another type of growth advantage,
and leads to the progressive conversion of normal cells into
cancer cells [1–3]. In fact, a wide array of chronic inflam-
matory conditions predisposes susceptible cells to neoplastic
transformations during this journey to carcinogenesis [4–5].
In general, the longer the inflammation persists, the
higher the risk of cancer, suggesting that though inflam-
mation is a step-by-step process that includes injury, repair
and resolution, all inflammatory cells, for instance, neutro-
phils, monocytes, macrophages, eosinophils, dendritic cells,
mast cells, and lymphocytes, are recruited after a damage or
an infection, and may contribute to the onset and progression
of cancer [6]. Moreover, once tumor develops, tumor cells
educated macrophages or inflammatory cells to promote
tumor progression. With the continuing medical education
that inflammatory cells including macrophages are continu-
ously educated by the tumor microenvironment, they adopt a
trophic role that facilitates angiogenesis, matrix breakdownY.J. Kim et al.
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and tumor cell motility, all of which are elements of the
metastatic process [7]. During an inflammatory response,
these inflammatory cells also produce many compounds,
ranging from mutagenic oxygen and nitrogen radicals to
angiogenic factors that further contribute to cancer initiation
and promotion [8]. Therefore, crudely saying, this is why
inflammation represents an important drug target for cancer
prevention and cure.
It has been reported that approximately 15–20% of all
malignancies are initiated or exacerbated by inflammation.
Furthermore, the recruitment and infiltration of inflam-
matory cells in the tumor microenvironment activates them
to spurt the malignant progression of cancer cells. Almost
150 years, Rudolf Virchow first indicated the concept that
lymphoreticular infiltration reflects the origin of cancer at
sites of chronic inflammation, suggesting a close connection
between inflammation and the development of cancer, of
which theory was further extended to implicate the stromal
interactions between malignant cells and inflammatory cells
associated with angiogenesis. Inflammatory stimuli include
chemicals and foreign bodies (e.g. asbestosis, fiber, silica
particles, catheters, alcohol, bile acids, gastric acids, gall
bladder stones, and ultraviolet light) and infectious organ-
isms (e.g. Helicobacter pylori (H. pylori), hepatitis B and C
viruses, Epstein-Barr virus, herpes virus, papilloma virus,
HIV) [9–10].
Irrespecive of involved organs and etiologies of inflam-
mations, the common features essential to inflammation-
associated carcinogenesis were as follows; proinflammatory
cytokines including tumor necrosis factor-α (TNF-α),
interleukin (IL)-1β, IL-6, IL-8, interferon-γ, MDM2, p53
etc, prevail in inflamed sites, imbalance between reactive
oxygen species (ROS)-generating enzymes and anti-oxidant
defense mechanisms, so called, oxidative stress, activation
of NF-κB, inducible nitric oxide synthase (iNOS), cyclo-
oxygenase-2 (COX-2), proteinase, and activation of onco-
genes. Based on these implications, various chemopreven-
tive agents targeted for attenuating inflammation have been
studies, including curcumin, retinoids, Vitamin E, silimarin,
aspirin, celecoxib, some plant polyphenols, proton pump
inhibitor and others [11–13].
Crosslink between H. pylori-Associated Chronic
Atrophic Gastritis and Gastric Cancer
Though it shows the tendency of decrease in gastric
cancer for last 80 years, it is still second highest cause of
death following lung cancer and in Korea. 25–30 people out
of 100,000 catch gastric cancer regardless of their gender
and its motility rate is number one. However, the discovery
of causative pathogen of gastric cancer, H. pylori, has shown
the light to inhibit gastric cancer because International
Agency for Research on Carcinogenesis (IARC, Lyon) in
1994 defined H. pylori as an imminent carcinogenic
pathogen based on many studies, epidemiological research
and animal studies. The definition has the historical back-
ground based on the theological evidence and several animal
experiments results showing infection of H. pylori causes
infiltration of inflammatory, oxidative damage and muta-
tions. In a resected specimen due to gastric cancer, the
intestinal metaplstic lesions were easily identified around
cancer lesions, for which H. pylori infection is closely
associated. The reason why gastric cancer is not controlled
even after killing H. pylori, is that under the equation:
“chronic atrophic gastritis–intestinal metaplasia-gastric
cancer”, the patients who did not stepping into malignant
process could be benefited from H. pylori-associated
carcinogenesis [14–15]. In other words, even though H.
pylori, defined as Class I carcinogen, are eradicated, the
inflammation itself remains in the stomach, thus it seems
that the control and the amelioration of gastric inflammation
itself is far more essential in cancer prevention rather than
the eradication of the pathogen itself. This inversely empha-
sizes that chronically continuation of gastritis has greater
chance of onset of gastric cancer than infection of H. pylori
itself. H. pylori-induced gastric cancer is based on chronic
atrophic gastritis as well as intestinal metaplasia, and gone
into the stage of dysplasia, resulting in intestinal gastric
cancer and accompanied by genetic or environmental
change synergistically to accelerate the formation of cancer.
With this background, genetic factors, toxicity of the
pathogen and environmental factors are orchestrated to
develop  H. pylori-induced gastric cancer from inflam-
mation, thus with broad category, alleviation or treatment
of inflammation would be the fundamentals to the preven-
tion of gastric cancer.
Rejuvenation of Atrophic Gastritis, It is Possible?
Then, we have another question whether atrophic gastritis
can be restored as before infection with either the removal of
bacteria or clearing gastric inflammation. In spite two recent
large-scale, prospective studies, both performed in high
risk population, have reported that H. pylori infection as a
definite risk factor for the development of gastric cancer,
the opposite premise that eradication of H. pylori infection is
an appropriate target for the prevention of gastric cancer is
still uncertain. Tree randomized, placebo-controlled trials
performed in China and Columbia demonstrated no signifi-
cant protective effect by H. pylori eradication [16–18],
whereas contradictory results have emerged out of three
Japanese studies published recently [19–21], indicating that
H. pylori eradication may prevent the development of gastric
cancer significantly, even in patients with precancerous
gastric lesions. These reciprocal results can be explained by
the fact that, unlike the studies from China and Columbia,Chemoprevention of Gastric Cancer with Korea Red Ginseng
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protective studies from Japan were neither randomized nor
placebo-controlled. However, the common evidence of each
Japanese study was that no gastric cancers developed after
eradication treatment in patients without precancerous
gastric lesions at entry. Stated the other way around, all
gastric cancer cases appeared in patients who had chronic
atrophic gastritis/intestinal metaplasia at trial entry before
H. pylori eradication. This observation ascertains us that
earlier eradication therapy or other kinds of efforts to lessen
gastric inflammation could be beneficial in high-risk popula-
tions to completely abolish overall gastric cancer risk arising
from chronic atrophic gastritis [22]. Another key issue
regarding the influence of H. pylori eradication on gastric
cancer prevention is the fact that atrophic gastritis is
reversible lesion after H. pylori eradication, leading to
hypothesis that H. pylori eradication could retard or reverse
gastric carcinogenesis before it reaches the stage of H.
pylori-associated chronic atrophic gastritis and/or dysplasia.
As clear evidence of merit of H. pylori eradication, Fukase
et al. [23] have published important results from a study
where, following endoscopic resection of early gastric
cancer, a group of patients in a randomized control trial were
subjected to H. pylori eradication treatment and monitored at
different time intervals. At 3 years, metachronous gastric
cancer had developed in only 9 of 255 patients in the eradi-
cation group compared with 24 of 250 patients in the control
group, a significant difference with indicates that pro-
phylactic eradication of H. pylori in atrophic gastritis can
substantially reduce gastric cancer rates.
However, similar to afore-mentioned implication of H.
pylori eradication on gastric cancer prevention, studies
examining the reversibility of precancerous lesions following
eradication of H. pylori also have provided conflicting
results. Among earlier studies, several reported that the
severity of gastric atrophy and intestinal metaplasia does not
change after treatment [24]. In contrast, another study has
suggested that gastric atrophy and some of intestinal meta-
plasia can improve after H. pylori eradication [25]. The
contradictory results can be explained by a fact that
significant proportions among the eradicated patients have
progression of premalignant lesions, already stepping to
pass a “point-of-no-return”. Therefore, the eradication of H.
pylori infection might not be beneficial if therapy is given
passing the “point-of-no-return”. However, it is very diffi-
cult to discriminate whether the gastric premalignant lesion
is passed such a “point-of-no-return” or not by conventional
endoscopy or histopathology [26–27]. Many efforts had
been made to find biomarkers or clinical findings that
suggest reversibility of gastric atrophy or intestinal meta-
plasia; ideally, these might adopt high throughput analytical
techniques, including microarray or proteomics [28]. Based
on these observations, we hypothesize that supplementary
or continuing suppressive way for gastric inflammation to
mitigate chronic gastric gastritis will be the next step for
gastric cancer prevention and we strongly send confidence
that Korea red ginseng can play tackling in the progression
of atrophic gastritis and tangle to revert to non-atrophic
gastritis.
Efficacy of Panax ginseng C.A. Meyer on “Cancer
Prevention” Purpose; Tangle the Progression of
Atrophic Gastritis
Before entering the description about the beneficial effects
of Korea red ginseng on H. pylori-associated atrophic
gastritis, we will briefly touch the cancer preventive action
of  Panax ginseng. The name ginseng comes from the
Chinese words “Jen Sheng”, meaning “man-herb”, based on
the humanoid shape of the root or rhizome of the plant,
which is the part of the plant most commonly consumed.
The name Panax means “all healing” (panacea), which
describes the traditional belief that ginseng has properties
to heal all aspects of the body. Even though there are several
different species of ginseng, two of the most commonly
used are P. ginseng (Chinese ginseng) and P. quinquefolius
(American ginseng), among which P. ginseng C.A. Meyer
(Araliaceae) has been used as a medicine by the people of
Eastern Asia for at least 2,000 years [29–31]. Native to
Korea, this red-berried plant, commonly called Korean
ginseng, is now open employed for diabetes, cardiovascular
diseases, neurodegenerative diseases, urological diseases
including sexual improvement, several kinds of viral dis-
eases, including various kinds of cancer.
A research of PubMed for “cancer” and “P. ginseng”
yields over 400 articles, signaling that P. ginseng apparently
mitigates cancer through their anti-inflammatory, anti-
oxidant, and apoptotic mechanisms to influence carcino-
genic process. Briefly stated, 1) inducing differentiation
[32]; ginseng’s induction of repair or reverse transformation
of cells into more differentiated cells has been noted in
hepatoma, melanoma, and teratocarcinoma cells, 2) reduced
effects from chemical carcinogens [33]; inhibitory effects on
the development of rat mammary adenocarcinoma induced
by methyl-N-nitrosourea and N-ethyl-N-nitrosourea admin-
istration, 3) mitigating inflammatory carcinogenesis [34];
ginseng reduced COX-2, iNOS, and NK-κB, 4) antioxidant
chemoprevention [35]; ginseng extracts have been shown
to scavenge reactive oxygen species (ROS) as well as lipid
peroxidation. As shown in Fig. 1A, electron spin resonance
(ESR) measurement showed direct antioxidative action of
Korea red ginseng extracts on Fenton reaction-induced
hydroxyl radicals, 5) induction of apoptosis [ 36]; active
components of ginsenoside induced direct executions of
apoptosis, 6) inhibition of proliferation [37]; inhibition of
cell cycle progression has been implicated as a chemo-
preventive mechanisms of ginsenosidesm Rh2 Rg3,  etc,Y.J. Kim et al.
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halting the metastasis in addition to tumorigenesis except
one study showing increased metastatic potential of P.
ginseng, 7) immnuomodulation [38]; mostly studied post-
operatively to encourage the recovery from surgery or
illness, 8) the relief of multi-drug resistance (MDR) [39];
chemosensitizing effect and reduced efflux pump activity
related to MDR mechanism, 9) anti-angiogenic or angio-
genic effect [ 40]; dual effects on angiogenesis imposing
anti-angiogenic action against carcinogenesis,but angio-
genic effects for healing. As for effective gradients of
ginseng, ginsenosides or ginseng saponins are the principal
active ingredients in ginseng and more than 40 different
Fig. 1. (A) ESR changes with red ginseng extracts. Electron spin resonance (JOEL, Tokyo, Japan) was performed using DMPO as
adductor to visualize hydroxyl radicals in the presence of 0.01 mg Korea red ginseng extracts. As the doses of Korea red
ginseng extracts were increased, scavenging action was observed more than 0.01 mg of red ginseng extracts, suggesting the
antioxidative action of Korea red ginseng. (B) Confocal imaging of 8-OHdG in gastric mucosal cells. In non-stimulated state, 8-
OHdG was mostly observed scattered in cytoplasm, whereas in the presence of H. pylori infection, the expressions of 8-OHdG
were increased in either cytoplasm or nucleus, suggesting that 8-OHdG might reflect oxidative stress after H. pylori infection.
Korea red ginseng was very effective in mitigating the 8-OHdG levels even after H. pylori infection.Chemoprevention of Gastric Cancer with Korea Red Ginseng
Vol. 46, No. 3, 2010
199
ginsenosides have been identified. Based on their structural
differences, they can be classified into three categories; the
panaxdiol group (e.g. Rb1, Rb2, Rc, Rd, Rg3, Rh2), the
panaxatriol group (e.g. Re, Rf, Rg1, Rg2, Rh1) and the
oleanolic group (e.g. Ro).
As representational study showing anti-carcinogenic
properties of ginseng, Dr. T.K. Yun issued human epidemio-
logy and well organized animal study in the Lancet
Oncology (2001) [41]. He investigated the effects of ginseng
consumption on the risk of cancers by interviewing 905
pairs of cases and controls matched by age, sex, and date of
admission to the Korea Cancer center Hospital, Seoul. As
results, a trend test showed a significantly decrease in the
frequency of cancer cases among those with the highest
ginseng intake for men (p<0.0001) and for women (p<0.05),
strongly support the hypothesis that ginseng has cancer pre-
ventive effects.
Korea Red Ginseng for Mitigating Helicobacter
pylori-Associated Gastric Diseases; Toggle Inflam-
matory Activities
Several studies in the filed of microbiology and immuno-
logy have demonstrated that ginseng exerts antioxidant,
anti-bacterial growth, and anti-inflammatory effects. Ginse-
noside Rb1 has been known to inhibit lipopolysaccharide
(LPS)-induced expression of the proinflammatory cytokine,
TNF-α, and acidic polysaccharide from ginseng have been
reported to inhibit the adherence of H. pylori to human
gastric epithelial cells. Also a growth inhibiting effect of
the ginseng fraction, panaxdiol, on H. pylori was suggested
in vitro with an MIC of 50 μg/ml [42–43]. In addition to
these anti-microbial actions of ginseng ingredients, it has
been documented that ginseng has distinctive actions on cell
growth in various carcinoma cells, through growth inhibi-
tion or cytotoxic effects in some cell lines, such as human
melanoma cells A375-S2, hepatoma cells SK-HEP-1, and
prostate cells LNCaP, but growth stimulating or protective
cells in other cell lines, such as neuroblastoma SHSY5Y and
keratinocyte HaCaT, have been reported, suggesting that
ginseng might provide diverse biological actions depending
on cell context [44–45]. Then, how about ginseng on H.
pylori-infected gastric mucosal cells?
First, we documented that Korea red ginseng could rescue
H. pylori-induced cytotoxicity [46]. In addition to rescuing
actions of Korea red ginseng, they mitigate the oxidative
stress-induced DNA mutation. Red ginseng extracts signifi-
cantly attenuated both H. pylori-induced DNA damage
assessed by comet assay, apoptosis measured by DNA
fragmentation, and expressions of 8-OH-dG (Fig. 1B) for
which inactivation of ERK1/2 signal transduction and
attenuation of caspase-3 activation were operated. Simuta-
neously, Korea red ginseng decreased the H. pylori-
stimulated IL-8 expression, suggesting that based on these
gastroprotective effects of ginseng against H. pylori-
associated gastric mucosal damages, red ginseng could be
used as a medicinal phytonutrient against H. pylori infection
(Fig. 2A).
Then, we extended our experiment to prove whether red
Fig. 2. (A) Rescuing effects of Korea red ginseng against H.
pylori-induced inflammation or cytotoxicity [46] Red
ginseng could block several pathways to H. pylori-
associated gastric damages including the connection
between inflammation and carcinogenesis. They can
block signal transduction pathway to inflammatory
signals, attenuate apoptosis execution, and repress redox
sensitive transcriptional activation. (B) Inhibitory activi-
ties and attenuated expression of 5-LOX with red
ginseng in H. pylori-infected gastric epithelial cells [47].
Besides of COX-2 activation after H. pylori infection,
H. pylori infection triggered 5-LOX activation, leading
to increased production of 5(S)-HETE. Red ginseng
showed efficient blockade to 5-LOX activation as
equivalently efficient to 5-LOX inhibitors, geraniin.Y.J. Kim et al.
J. Clin. Biochem. Nutr.
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ginseng extract influences 5-lipoxygenase (5-LOX) pathway,
thereby suppressing the biosynthesis of 5(S)-HETE [47].
H. pylori infection increased exclusively 5-LOX enzyme
activity, which is strongly associated with carcinogenic
pathway. Red ginseng extracts inhibited these increments of
H. pylori-stimulated 5-LOX through inactivation of c-jun
phosphorylation and redox-sensitive transcriptional activa-
tion together, finally led to reduced levels of IL-8 and 5-
LOX in gastric mucosal cells (Fig. 2B). The LOX inhibiting
capacity of red ginseng was equivalent to 200 μM of
Fig. 3. Rejuvenation of atrophic gastritis with Korea red ginseng (A) Updated Sydney system to score the degree of gastric atrophy.
Two examples of atrophic gastritis and intestinal metaplasia (B) Changes of gastric atrophy. OAC 1W stands for 1 week of tri-
ple therapy including omeprazole, amoxicillin and clarithromycin [48]. Simply successful eradication of H. pylori alone could
led to improvement of gastric atrophy in around 30% of cases, but OAC 1W plus 10 weeks of Korea red ginseng supple-
mentation resulted in statistically significantly increment in improvement of gastric atrophy (p<0.05), signifying that rejuvena-
tion of gastric atrophy can be accelerated with Korea red ginseng supplementation after eradication regimen.Chemoprevention of Gastric Cancer with Korea Red Ginseng
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geraniin or EGTA.
All of our study described above for the first time,
revealed the H. pylori infection induced significant levels of
5-LOX activity rather than its expression and documented
the apparent biosynthesis of its metabolite, 5-HETE, which
eventually contributes to inflammatory activities through
LTB4 formation. Red ginseng treatment was efficient in
decreasing H. pylori-induced 5-LOX activities and attenu-
ating 5-LOX expression through inactivating c-jun pathway.
Several studies showed NSAID played significant chemo-
Fig. 4. Changes of 8-OHdG expressions in the biopsied gastric tissue (A) Change of 8-OHdG in placebo control group [48]. Though
H. pylori was successfully eradication with triple therapy, biopsied tissue obtained after 10weeks of H. pylori eradication
showed the remaining of gastric inflammatory activities. Therefore, 8-OHdG expressions were decreased in a scant level
compared to the levels before eradication. This finding suggest that simple removal of bug was not so efficient in attenuating 8-
OHdG levels, biomarker of oxidative stress related to H. pylori infection (B) Change of 8-OHdG in Korea red ginseng treated
group. In contrast to placebo group, the levels of 8-OHdG expression were significantly decreased in case, who were admin-
istered with supplementary red ginseng after eradication regimen, in spite of failure in eradication. These finding necessitates
the supplementation of Korea red ginseng to tackle the oxidative stress imposed by H. pylori infection.Y.J. Kim et al.
J. Clin. Biochem. Nutr.
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preventive effects against H. pylori-induced gastric carcino-
genesis through attenuating COX activities, but our study
opens the possibility that LOX activity as much as COX
activity might influence the inflammatory or carcinogenic
activities related to its disasters associated with H. pylori
infection, suggesting that modulation of activities of both
COX and LOX will be quite beneficial in avoiding the
deleterious outcomes of chronic H. pylori infection.
Tackle the Progression of Chronic Atrophic Gastritis
with Korea Red Ginseng
As Korea red ginseng has been reported to show a signifi-
cant protective effect against H. pylori-induced cytotoxicity
and DNA damage in vitro, we designed a clinical study to
assess the efficacy of red ginseng treatment in patients with
H. pylori-associated chronic gastritis [48]. A total of 84
patients with H. pylori-associated chronic gastritis were
recruited and randomly divided into two groups. During the
trial, 34 patients out of 42 patients in the placebo control
group and 36 patients out of 42 patients in the red ginseng
group completed the protocol. The patients received a one
week triple therapy for the eradication of H. pylori and then
received either placebo capsules that were composed of
flour for the placebo group or red ginseng capsules for the
treatment group, which were administered for 10 weeks. An
endoscopic examination of gastritis with a visual analogue
scale, a test for detection of H. pylori, immunohisto-
chemistry of 8-OHdG, the 8-OHdG immunohistochemical
staining for assessing oxidative DNA damage and TUNEL
staining for apoptosis were performed, respectively. As
results, H. pylori eradication rates were augmented in the
red ginseng group as compared to the placebo group (91.7%
in the red ginseng group and 79.4% in the placebo group),
but there was no statistical significance (p = 0.147). For an
analysis of gastritis based on Updated Sydney System
(Fig. 3A), the red ginseng group showed significant
improvement in neutrophil infiltrations (p = 0.008), chronic
atrophic gastritis (Fig. 3B, p<0.05), and even intestinal
metaplasia (p = 0.005). An attenuation of 8-OHdG immuno-
histostaining after treatment was seen more frequently in
the red ginseng group (p<0.001) (Fig. 4). An attenuation of
DNA damage and apoptosis was seen for the red ginseng
group as compared to the placebo group (p<0.001). There-
fore, supplementary administration of red ginseng augmented
eradication rates of H. pylori, attenuated gastric inflam-
mation, and reduced oxidative DNA damage and apoptosis,
suggesting the clinical usefulness of red ginseng.
Recently we could add more evidence that Korea red
ginseng was very efficient in eliminating troublesome
halitosis. Since halitosis is closely associated with erosive
changes in the stomach [49], the halitosis improving actions
of Korea red ginseng were dependent on either direct
suppressive action of Korea red ginseng on enzyme respon-
sible for generating volatile sulfure compounds, that is,
cystathionine γ-lyase and cystathionine β-synthase, or cyto-
restorative actions [50].
Perspective
Ginseng has been reported to reduce the human cancer
risk of lip, oral cavity, pharynx, larynx, esophagus, lung,
liver, pancreas, ovary, colon, rectum, and stomach docu-
mented by clinical and epidemiological studies, rendering
Panax ginseng as “non-organ specific cancer preventive”
[41]. However, still many people have questioned the use
of traditional medicinal herbs and this has been a prime issue
in complementary and alternative medicine. Even though we
issued several in vitro and in vivo results of feasibility of
Korea red ginseng administration for mitigating H. pylori-
associated atrophic changes and carcinogenesis, science and
evidence based medicine must develop through verification
of observations, necessitating that the need for clinical
studies should be strongly recommended, especially more to
put Korea red ginseng as “H. pylori-associated gastric
cancer preventive” based on our publications [46–48, 51].
Scientific clinical trials of Korea red ginseng are now
warranted to reach to the conclusion that rejuvenation of
atrophic gastritis could be coming true with supplementation
of Korea red ginseng after the eradication of H. pylori
infection. Overall, ginseng is a good example of a natural
herb that has ubiquitous properties that are conductive to
stopping inflammatory carcinogenesis.
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